Technology

IGM Biosciences has been exclusively focused on the research, development and production of IgM and IgA antibodies since 2011.

We have developed skill, knowledge and intellectual property that is essential to the successful protein engineering, expression, purification and formulation of J chain containing antibodies (IgM and IgA).

Our technology, experience and skill has enabled the creation of:

  • Multi-valent agonist antibodies
  • Asymmetric bi-specific antibodies
  • Extended and variable half-life antibodies
  • T cell engaging bispecific antibodies
  • NK cell engaging bispecific antibodies
  • Immune checkpoint antibodies, both monospecific and bispecific
  • Antibodies with variable levels of complement activity
  • Antibodies designed to improve tissue transport

We have taken an IgM antibody through GLP and GMP manufacturing at 500 liter scale, and we have developed efficient purification and stable formulations of IgM antibodies. Vialed drug from our first GMP manufacturing run has demonstrated stability at two years, and continued stability testing is ongoing.

We have extensive experience at converting IgG antibody binding sequences into IgM and IgA antibodies, as we believe that in IgM or IgA format those sequences will often benefit from certain inherent advantages of IgM or IgA antibodies, including (i) stronger binding to low expression cell surface targets and difficult targets such as carbohydrates, (ii) greater ability to cross-link cell surface receptors for vastly increased cellular signaling, (iii) improved complement dependent cytoxicity (CDC), and (iv) improved antibody dependent cellular phagocytosis (ADCP).

We have also expanded the rationale for IgM and IgA conversion from IgG to include synthesis of novel bispecific antibodies.  We believe that in certain clinical applications our asymmetric bispecific antibody technology is intrinsically superior.  These applications include those circumstances in which the ability to direct 10 binding units to a low expression or difficult target and one binding unit to an immune effector cell or an immune checkpoint or immune stimulant is expected to produce more efficacious or safer performance.

In the case of T cell directed killing, our IgM based bispecific technology has demonstrated an enhanced safety profile in terms of cytokine release, as compared to an IgG based bispecific.

We have an extensive portfolio of internationally granted patents and patent applications with respect to IgM and IgA antibodies, and we continue to aggressively pursue patent protection with respect to our technology and our product candidates.